<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39326809</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-1899</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><PubDate><Year>2024</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Biotechnology advances</Title><ISOAbbreviation>Biotechnol Adv</ISOAbbreviation></Journal><ArticleTitle>Bioengineered heparin: Advances in production technology.</ArticleTitle><Pagination><StartPage>108456</StartPage><MedlinePgn>108456</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biotechadv.2024.108456</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0734-9750(24)00150-2</ELocationID><Abstract><AbstractText>Heparin, a highly sulfated glycosaminoglycan, is considered an indispensable anticoagulant with diverse therapeutic applications and has been a mainstay in medical practice for nearly a century. Its potential extends beyond anticoagulation, showing promise in treating inflammation, cancer, and infectious diseases such as COVID-19. However, its current sourcing from animal tissues poses challenges due to variable structures and adulterations, impacting treatment efficacy and safety. Recent advancements in metabolic engineering and synthetic biology offer alternatives through bioengineered heparin production, albeit with challenges such as controlling molecular weight and sulfonation patterns. This review offers comprehensive insight into recent advancements, encompassing: (i) the metabolic engineering strategies in prokaryotic systems for heparin production; (ii) strides made in the development of bioengineered heparin; and (iii) groundbreaking approaches driving production enhancements in eukaryotic systems. Additionally, it explores the potential of recombinant Chinese hamster ovary cells in heparin synthesis, discussing recent progress, challenges, and future prospects, thereby opening up new avenues in biomedical research.</AbstractText><CopyrightInformation>Copyright Â© 2024 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sultana</LastName><ForeName>Razia</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan; Department of Biotechnology and Genetic Engineering, Faculty of Science, Noakhali Science and Technology University, Noakhali 3814, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamihira</LastName><ForeName>Masamichi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan. Electronic address: kamihira@chem-eng.kyushu-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biotechnol Adv</MedlineTA><NlmUniqueID>8403708</NlmUniqueID><ISSNLinking>0734-9750</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anticoagulant drug</Keyword><Keyword MajorTopicYN="N">Bioengineered heparin</Keyword><Keyword MajorTopicYN="N">Glycosaminoglycan</Keyword><Keyword MajorTopicYN="N">Metabolic engineering</Keyword><Keyword MajorTopicYN="N">Synthetic biology</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39326809</ArticleId><ArticleId IdType="doi">10.1016/j.biotechadv.2024.108456</ArticleId><ArticleId IdType="pii">S0734-9750(24)00150-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle>